Amgen, Arrowhead team up on gene-therapies for heart disease

(Reuters) - Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files

Arrowhead will get $35 million up front and a $21.5 million injection from Amgen that will give the world’s No. 1 biotech company by market value an equity stake of 4.5 percent.

Pasadena, California-based Arrowhead will also eligible for up to $617 million in further milestone and equity payments.

Shares of the company, whose shareholders include BlackRock Inc, Novartis AG and JPMorgan Chase & Co, rose as much as 15 percent to $8.09 in early trading.

Arrowhead, along with competitors such as Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc and privately held Quark Pharmaceuticals, focuses on ribonucleic acid interference (RNAi), which aims to silence certain genes to curb the production of disease-causing proteins.

RNAi has long interested drug developers, but has frequently met with clinical failure.

Existing drugs, including monoclonal antibodies, work by trying to inactivate disease-causing proteins by binding to them.

The license and collaboration deal includes two agreements, under which Thousand Oaks, California-based Amgen will take charge of clinical development and commercialization.

Under the first agreement, Amgen will get an exclusive global license to Arrowhead’s ARC-LPA program, which has not been tested in humans.

The RNAi drug is designed to reduce elevated levels of a form of cholesterol called Lp(a) that raises the risk of heart disease caused by plaque build-up.

One in five people inherit high levels of Lp(a), which leads to the gradual narrowing of arteries, limiting blood supply to the heart, brain, kidneys and legs, thereby raising the risk of blood clots, heart attack and stroke.

So far, there is no treatment for the condition.

Under the second agreement, Amgen will receive an option to an exclusive global license for a RNAi therapy for an undisclosed cardiovascular target.

Amgen has a growing suite of cardiovascular therapies, both on the market and in development.

These include its potent, expensive new cholesterol fighter Repatha, chronic heart failure treatment Corlanor, and omecamtiv mecarbil, which is in the final stages of development.

Amgen announced last September that it would buy biotechnology company Dezima Pharma BV, adding another cholesterol drug to its pipeline.

Amgen’s shares were down 0.4 percent at $169.07.

Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr